Author(s): Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011 Jun;54(6):1335-40. doi: 10.1007/s00125-011-2096-6. Epub 2011 Mar 5. PMID 21380596
Journal: Diabetologia, Volume 54, Issue 6, Jun 2011
AIMS/HYPOTHESIS To examine the association of serum cystatin C with the incidence of type 2 diabetes mellitus over a 15 year follow-up period.
METHODS The 15 year cumulative incidence of diabetes was measured in a cohort of Beaver Dam Eye Study participants (n = 3,472, 1988-2003). A person was defined as developing diabetes (a positive history of diabetes mellitus treated with insulin, oral hypoglycaemic agents and/or diet, or elevations in glycosylated haemoglobin levels) in the absence of diabetes at baseline. The relation of cystatin C and other risk factors to incident type 2 diabetes was determined using discrete time extension of the proportional hazards model.
RESULTS The 15 year cumulative incidence of diabetes was estimated to be 9.6%. After controlling for age, sex, body mass index, smoking status, glycosylated haemoglobin, proteinuria, chronic kidney disease status and hypertension status, serum cystatin C at baseline was associated with the 15 year cumulative incidence of type 2 diabetes (OR per log of cystatin C unit 2.19, 95% CI 1.02-4.68).
CONCLUSIONS/INTERPRETATION These findings show a positive relationship of serum cystatin C levels with the incidence of type 2 diabetes mellitus independently of confounding risk factors. The findings strongly suggest the need for further evaluation of the potential importance of cystatin C in the pathogenesis of type 2 diabetes mellitus.